Advertisement

Topics

Supercomputing 2014 Company Profile

01:03 EST 13th December 2018 | BioPortfolio


News Articles [174 Associated News Articles listed on BioPortfolio]

The Obesity Paradox in RCC

Although being overweight does increase the risks for renal cell cancer (RCC), a recent study from Dr. Albiges and colleagues from ASCO 2014 shows that overweight or obese patients with kidney cancer ...

What Is Non-Clear Cell Kidney Cancer?

Among kidney cancer patients, the sub-type “non-clear cell” is the least common. As a result, not much research has been conducted on it.Related Posts:No C

How is the Heng Criteria Applied to Kidney Cancer Patients?

Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.Related Posts:Evaluating Biomarkers in Kidney Cancer August...

Evaluating Biomarkers in Kidney Cancer

Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient’s cancer is likely to recur. Dr. Daniel Heng discusses what researche...

Can Systemic Therapy Wait?

Patients with metastatic renal cell carcinoma (mRCC) with an indolent growth pattern may be able to put off systemic therapy and be observed for a period of time instead. Dr. Rini and colleagues prese...

No Clear Answer for Non-Clear Cell Kidney Cancer

Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.Related Posts:

Facilitating Partial Nephrectomy with Pre-Operative Pazopanib

When a patient has a localized renal mass, a partial nephrectomy is the desired surgical approach because it preserves renal function. Depending on the tumor size and location, a partial nephrectomy i...

Treating Newly Diagnosed Kidney Cancer

Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.Related Posts:Kidney Cancer Immunotherapy: PD-1 Pathway Clinical&helli...

Drugs and Medications [0 Results]

None

PubMed Articles [422 Associated PubMed Articles listed on BioPortfolio]

Trends in Socioeconomic Disparities in Obesity Prevalence among Low-Income Children Aged 2-4 Years in Los Angeles County, 2003-2014.

Obesity prevalence among low-income preschool-aged children in the United States decreased between 2010 and 2014. However, this decreasing trend may be varied across socioeconomic subgroups. This stud...

The Economic and Social Burden of the 2014 Ebola Outbreak in West Africa.

The 2014 Ebola virus disease (EVD) outbreak in West Africa was more devastating than all previous EVD outbreaks combined; however, many estimates of its economic burden did not capture its significant...

Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014-2017.

Pakistan began using inactivated poliovirus vaccine alongside oral vaccine in mass campaigns to accelerate eradication of wild-type poliovirus in 2014. Using case-based and environmental surveillance ...

Lack of Change in Perinatal Mortality in the United States, 2014-2016.

Perinatal mortality (late fetal death at 28 weeks or more and early neonatal death under age 7 days) can be an indicator of the quality of health care before, during, and after delivery (1,2). The U.S...

Annual Report on Healthcare for Children and Youth in the United States: Focus on 30-day unplanned inpatient readmissions, 2009-2014.

The aim of this study is to describe trends in unplanned 30-day all-condition hospital readmissions for children aged 1 to 17 years between 2009 and 2014.

Clinical Trials [468 Associated Clinical Trials listed on BioPortfolio]

A Phase I, Three-part Study to Determine the Maximum Tolerated Dose/Recommended Dose, Compare Bioavailability in the Fed and Fasted States, and Evaluate Safety and Tolerability of ORH-2014 in Subjects With Advanced Hematological Disorders

Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses. Subjects with the following advanced hematological disord...

Fusarium Keratitits in Spain 2012 to 2014

The aim of this study was to describe the clinical-epidemiological characteristics of a series of cases of fungal keratitis associated with Fusarium spp., In Spain during the years 2012 to...

Tramadol in Penial Block Does it Improve Efficiency of Postoperative Analgesia in Circumcision

After the consent of the local ethics committee and informed consent of the parents, we conducted a prospective randomized, double-blind study, from 30 June 2014 to 31 December 2014, inclu...

Deep Brain Stimulation in HUCH Region Between 2006 and 2014

This study reviews the outcome of deep brain stimulation treated patients in Helsinki and Uusimaa University Hospital between 2006 and 2014. The aim of the study is to investigate the outc...

The Immunogenicity and Safety of 2013-2014 Trivalent Seasonal Influenza Vaccine

The purpose of this study is to evaluate the immunogenicity and safety of 2013-2014 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged ...

Companies [249 Associated Companies listed on BioPortfolio]

NantWorks LLC

NantWorks LLC was recently founded and led by Patrick Soon-Shiong, MD. Its mission is to converge semiconductor technology, supercomputing, advanced networks and augmented intelli...

NeuroTherapeutics Pharma, Inc.

NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorder...

Freed Associates

At Freed Associates, healthcare is their passion and their business. Founded by Dava Freed in 1991, Freed Associates consults with healthcare organizations on strategic and tactic...

Intellia Therapeutics

Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technolo...

Baker Marquart LLP on behalf of Federico Pignatelli

Mr. Pignatelli served on the BIOLASE Board of Directors continuously from 1991 through August 2014 and is currently the beneficial owner of approximately 1.8 million shares of BIO...

More Information about "Supercomputing 2014" on BioPortfolio

We have published hundreds of Supercomputing 2014 news stories on BioPortfolio along with dozens of Supercomputing 2014 Clinical Trials and PubMed Articles about Supercomputing 2014 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Supercomputing 2014 Companies in our database. You can also find out about relevant Supercomputing 2014 Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record